Screening HIV-infected individuals for anal cancer precursor lesions: A systematic review

Clinical Infectious Diseases

Volumn 43, Issue 2, 2006, Pages 223-233

  Chiao, Elizabeth Y ^a,b   Giordano, Thomas P ^a,b   Palefsky, Joel M ^d   Tyring, Stephen ^c   Serag, Hashem El ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ANUS CANCER; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CD4 LYMPHOCYTE COUNT; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DISABILITY; DISEASE COURSE; DRUG EFFICACY; EARLY DIAGNOSIS; HEALTH CARE COST; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PAPANICOLAOU TEST; PREVALENCE; PRIORITY JOURNAL; REVIEW; SQUAMOUS CELL CARCINOMA; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UTERINE CERVIX CANCER; WART VIRUS;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANUS NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, SQUAMOUS CELL; FEMALE; HIV INFECTIONS; HUMANS; MALE; MASS SCREENING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PRECANCEROUS CONDITIONS; VAGINAL SMEARS;

EID: 33745714442     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/505219     Document Type: Review

References (100)

1. Johnson LG, Madeleine MM, Newcomer LM, Schwartz SM, Daling JR. Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973-2000. Cancer 2004; 101:281-8.
2. Chiao EY, Krown SE, Stier EA, Schrag D. A population-based analysis of temporal trends in the incidence of squamous anal canal cancer in relation to the HIV epidemic. J Acquir Immune Defic Syndr 2005; 40:451-5.
3. Melbye M, Rabkin C, Frisch M, Biggar RJ. Changing patterns of anal cancer incidence in the United States, 1940-1989. Am J Epidemiol 1994; 139:772-80.
4. Frisch M, Smith E, Grulich A, Johansen C. Cancer in a population-based cohort of men and women in registered homosexual partnerships. Am J Epidemiol 2003; 157:966-72.
5. Daling JR, Weiss NS, Hislop TG, et al. Sexual practices, sexually transmitted diseases, and the incidence of anal cancer. N Engl J Med 1987; 317:973-7.
6. Frisch M, Biggar RJ, Engels EA, Goedert JJ. Association of cancer with AIDS-related immunosuppression in adults. JAMA 2001; 285:1736-45.
7. Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 2000; 92:1500-10.
8. Goedert JJ, Cote TR, Virgo P, et al. Spectrum of AIDS-associated malignant disorders. Lancet 1998; 351:1833-9.
9. Bjorge T, Engeland A, Luostarinen T, et al. Human papillomavirus infection as a risk factor for anal and perianal skin cancer in a prospective study. Br J Cancer 2002; 87:61-4.
10. Durante AJ, Williams AB, Da Costa M, Darragh TM, Khoshnood K, Palefsky JM. Incidence of anal cytological abnormalities in a cohort of human immunodeficiency virus-infected women. Cancer Epidemiol Biomarkers Prev 2003; 12:638-42.
11. Palefsky JM, Holly EA, Gonzales J, Berline J, Ahn DK, Greenspan JS. Detection of human papillomavirus DNA in anal intraepithelial neoplasia and anal cancer. Cancer Res 1991; 51:1014-9.
12. Zaki SR, Judd R, Coffield LM, Greer P, Rolston F, Evatt BL. Human papillomavirus infection and anal carcinoma: retrospective analysis by in situ hybridization and the polymerase chain reaction. Am J Pathol 1992; 140:1345-55.
13. Goldman S, Auer G, Erhardt K, Seligson U. Prognostic significance of clinical stage, histologic grade, and nuclear DNA content in squamous-cell carcinoma of the anus. Dis Colon Rectum 1987; 30:444-8.
14. Jay N, Berry JM, Hogeboom CJ, Holly EA, Darragh TM, Palefsky JM. Colposcopic appearance of anal squamous intraepithelial lesions: relationship to histopathology. Dis Colon Rectum 1997; 40:919-28.
15. Sackett D, Hayhes R, Guyatt G, et al. Early diagnosis. In: Sackett D, Hayhes R, Guyatt G, et al., eds. Clinical epidemiology: a basic science for clinical medicine. Boston: Little, Brown, 1991:153-70.
16. Gallagher B, Wang Z, Schymura MJ, Kahn A, Fordyce EJ. Cancer incidence in New York State acquired immunodeficiency syndrome patients. Am J Epidemiol 2001; 154:544-56.
17. Biggar RJ, Kirby KA, Atkinson J, McNeel TS, Engels E. Cancer risk in elderly persons with HIV/AIDS. J Acquir Immune Defic Syndr 2004; 36:861-8.
18. Diamond C, Taylor TH, Aboumrad T, Bringman D, Anton-Culver H. Increased incidence of squamous cell anal cancer among men with AIDS in the era of highly active antiretroviral therapy. Sex Transm Dis 2005; 32:314-20.
19. Clifford GM, Polesel J, Rickenbach M, et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005; 97:425-32.
20. Grulich AE, Wan X, Law MG, Coates M, Kaldor JM. Risk of cancer in people with AIDS. AIDS 1999; 13:839-43.
21. Petruckevitch A, Del Amo J, Phillips AN, Stephenson JM, Johnson AM, De Cock KM. Risk of cancer in patients with HIV disease. London African HIV/AIDS Study Group. Int J STD AIDS 1999; 10:38-42.
22. Bower M, Powles T, Newsom-Davis T, et al. HIV-associated anal cancer: has highly active antiretroviral therapy reduced the incidence or improved the outcome? J Acquir Immune Defic Syndr 2004; 37:1563-5.
23. Cleator S, Fife K, Nelson M, Gazzard B, Phillips R, Bower M. Treatment of HIV-associated invasive anal cancer with combined chemoradiation. Eur J Cancer 2000; 36:754-8.
24. Stadler RF, Gregorcyk SG, Euhus DM, Place RJ, Huber PJ, Simmang CL. Outcome of HIV-infected patients with invasive squamous-cell carcinoma of the anal canal in the era of highly active antiretroviral therapy. Dis Colon Rectum 2004; 47:1305-9.
25. Bottomley DM, Aqel N, Selvaratnam G, Phillips RH. Epidermoid anal cancer in HIV infected patients. Clin Oncol (R Coll Radiol) 1996; 8:319-22.
26. Hocht S, Wiegel T, Kroesen AJ, Berdel WE, Runkel N, Hinkelbein W. Low acute toxicity of radiotherapy and radiochemotherapy in patients with cancer of the anal canal and HIV-infection. Acta Oncol 1997; 36:799-802.
27. Peddada AV, Smith DE, Rao AR, Frost DB, Kagan AR. Chemotherapy and low-dose radiotherapy in the treatment of HIV-infected patients with carcinoma of the anal canal. Int J Radiat Oncol Biol Phys 1997; 37:1101-5.
28. Hoffman R, Welton ML, Klencke B, Weinberg V, Krieg R. The significance of pretreatment CD4 count on the outcome and treatment stolerance of HIV-positive patients with anal cancer. Int J Radiat Oncol Biol Phys 1999; 44:127-31.
29. Blazy A, Hennequin C, Gornet JM, et al. Anal carcinomas in HIV-positive patients: high-dose chemoradiotherapy is feasible in the era of highly active antiretroviral therapy. Dis Colon Rectum 2005; 48:1176-81.
30. Arain S, Walts AE, Thomas P, Bose S. The anal Pap smear: cytomorphology of squamous intraepithelial lesions. Cytojournal 2005; 2:4.
31. Papaconstantinou HT, Lee AJ, Simmang CL, et al. Screening methods for high-grade dysplasia in patients with anal condyloma. J Surg Res 2005; 127:8-13.
32. Palefsky JM, Holly EA, Hogeboom CJ, Berry JM, Jay N, Darragh TM. Anal cytology as a screening tool for anal squamous intraepithelial lesions. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14:415-22.
33. Mathews WC, Sitapati A, Caperna JC, Barber RE, Tugend A, Go U. Measurement characteristics of anal cytology, histopathology, and high-resolution anoscopic visual impression in an anal dysplasia screening program. J Acquir Immune Defic Syndr 2004; 37:1610-5.
34. Lee A, Young T, Hanks D, Ung R, Stansell J. The evaluation of anal dysplasia with anal cytology (Pap) followed by high resolution anoscopy (HRA) and biopsy in HIV-infected men [abstract ThOrB1407]. Int Conf AIDS 2004; 15.
35. Panther LA, Wagner K, Proper J, et al. High resolution anoscopy findings for men who have sex with men: inaccuracy of anal cytology as a predictor of histologic high-grade anal intraepithelial neoplasia and the impact of HIV serostatus. Clin Infect Dis 2004; 38:1490-2.
36. Fox PA, Seet JE, Stebbing J, et al. The value of anal cytology and human papillomavirus typing in the detection of anal intraepithelial neoplasia: a review of cases from an anoscopy clinic. Sex Transm Infect 2005; 81:142-6.
37. Salit I, Tinmouth J, Lytwyn A, et al. Anal cancer screening: test characteristics of cytology and oncolgenic HPV testing for the detection of anal dysplasia [abstract 899]. In: Program and abstracts of the 12th Annual Conference on Retroviruses and Opportunistic Infections. 2005.
38. Chang GJ, Berry JM, Jay N, Palefsky JM, Welton ML. Surgical treatment of high-grade anal squamous intraepithelial lesions: a prospective study. Dis Colon Rectum 2002; 45:453-8.
39. Goldstone SE, Kawalek AZ, Huyett JW. Infrared coagulator: a useful tool for treating anal squamous intraepithelial lesions. Dis Colon Rectum 2005; 48:1042-54.
40. Kreuter A, Hochdorfer B, Stucker M, et al. Treatment of anal intraepithelial neoplasia in patients with acquired HIV with imiquimod 5% cream. J Am Acad Dermatol 2004; 50:980-1.
41. Graham BD, Jetmore AB, Foote JE, Arnold LK. Topical 5-fluorouracil in the management of extensive anal Bowen's disease: a preferred approach. Dis Colon Rectum 2005; 48:444-50.
42. Pehoushek J, Smith KJ. Imiquimod and 5% fluorouracil therapy for anal and perianal squamous cell carcinoma in situ in an HIV-1-positive man. Arch Dermatol 2001; 137:14-6.
43. Klencke B, Matijevic M, Urban RG, et al. Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a phase I study of ZYC101. Clin Cancer Res 2002; 8:1028-37.
44. Palefsky JM, Goldstone SE, Neefe J. HspE7 treatment of high-grade anal dysplasia: final results of an open-label trial and interim long-term follow-up. 20th International Papillomavirus Conference. 2002.
45. Palefsky JM, Holly EA, Ralston ML, et al. Effect of highly active antiretroviral therapy on the natural history of anal squamous intraepithelial lesions and anal human papillomavirus infection. J Acquir Immune Defic Syndr 2001; 28:422-8.
46. Palefsky JM, Holly EA, Efirdc JT, et al. Anal intraepithelial neoplasia in the highly active antiretroviral therapy era among HIV-positive men who have sex with men. AIDS 2005; 19:1407-14.
47. Piketty C, Darragh TM, Heard I, et al. High prevalence of anal squamous intraepithelial lesions in HIV-positive men despite the use of highly active antiretroviral therapy. Sex Transm Dis 2004; 31:96-9.
48. Kiviat NB, Redman M, Hawes S, Lampinen T, Nelspon P, Critchlow CW. The effect of HAART on detection of anal HPV and squamous intraepithelial lesions among HIV infected homosexual men. 6th International Conference on Malignancies in AIDS and Other Immunodeficiencies. 2002.
49. Wilkin TJ, Palmer S, Brudney KR Chiasson MA, Wright TC. Anal intraepithelial neoplasia in heterosexual and homosexual HIV-positive men with access to antiretroviral therapy. J Infect Dis 2004; 190:1685-91.
50. Piketty C, Darragh TM, Da Costa M, et al. High prevalence of anal human papillomavirus infection and anal cancer precursors among HIV-infected persons in the absence of anal intercourse. Ann Intern Med 2003; 138:453-9.
51. Palefsky JM, Holly EA, Ralston ML, Jay N. Prevalence and risk factors for human papillomavirus infection of the anal canal in human immunodeficiency virus (HIV)-positive and HIV-negative homosexual men. J Infect Dis 1998; 177:361-7.
52. Friedman HB, Saah AJ, Sherman ME, et al. Human papillomavirus, anal squamous intraepithelial lesions, and human immunodeficiency virus in a cohort of gay men. J Infect Dis 1998; 178:45-52.
53. Lacey HB, Wilson GE, Tilston P, et al. A study of anal intraepithelial neoplasia in HIV positive homosexual men. Sex Transm Infect 1999; 75:172-7.
54. Kreuter A, Brockmeyer NH, Hochdorfer B, et al. Clinical spectrum and virologic characteristics of anal intraepithelial neoplasia in HIV infection. J Am Acad Dermatol 2005; 52:603-8.
55. Chin-Hong PV, Guimaraes MD, Bonfim D, et al. Anal squamous intraepithelial lesions and HPV infection in HIV-positive men in Brazil [abstract WePeC6068]. Int Conf AIDS 2004; 15.
56. Alfonzo R, Uribe M, Cavazza ME, et al. Anal cytology screening as a useful test for diagnosis of anal dysplasia in HIV positive patients [abstract ThPeC7599]. Int Conf AIDS 2002.
57. Fine S, Castiglia J, Corales R, et al. Anal Pap smears in HIV+ patients at a community based clinic [abstract ThPeC7488]. Int Conf AIDS 2002.
58. Norton M, Milano D, Vane C, Beaumont F. Practicality of and results from rectal Pap pmears among patients receiving primary HIV care at a community health center, NYC, USA. IAS Conference on HIV Pathogenesis and Treatment. 2003.
59. Hillemanns P, Ellerbrock TV, Dole P, Sun XW, Chiasson MA, Wright TC. Anal HPV infection and anal cytologic abnormalities in HIV-seropostiive women. Internation Conference on AIDS. 1996.
60. Palefsky JM, Holly EA, Ralston ML, Da Costa M, Greenblatt RM. Prevalence and risk factors for anal human papillomavirus infection in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women. J Infect Dis 2001; 183:383-91.
61. Holly EA, Ralston ML, Darragh TM, Greenblatt RM, Jay N, Palefsky JM. Prevalence and risk factors for anal squamous intraepithelial lesions in women. J Natl Cancer Inst 2001; 93:843-9.
62. Melbye M, Smith E, Wohlfahrt J, et al. Anal and cervical abnormality in women-prediction by human papillomavirus tests. Int J Cancer 1996; 68:559-64.
63. Sayers SJ, McMillan A, McGoogan E. Anal cytological abnormalities in HIV-infected homosexual men. Int J STD AIDS 1998; 9:37-40.
64. Goldstone SE, Winkler B, Ufford LJ, Alt E, Palefsky JM. High prevalence of anal squamous intraepithelial lesions and squamous-cell carcinoma in men who have sex with men as seen in a surgical practice. Dis Colon Rectum 2001; 44:690-8.
65. Palefsky JM, Holly EA, Ralston ML, Jay N, Berry JM, Darragh TM. High incidence of anal high-grade squamous intra-epithelial lesions among HIV-positive and HIV-negative homosexual and bisexual men. AIDS 1998; 12:495-503.
66. Goldie SJ, Kuntz KM, Weinstein MC, Freedberg KA, Welton ML, Palefsky JM. The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men. JAMA 1999; 281:1822-9.
67. Dal Maso L, Franceschi S, Polesel J, et al. Risk of cancer in persons with AIDS in Italy, 1985-1998. Br ) Cancer 2003; 89:94-100.
68. Fordyce EJ, Wang Z, Kahn AR, et al. Risk of cancer among women with AIDS in New York City. AIDS Public Policy J 2000; 15:95-104.
69. Serraino D, Carrieri P, Pradier C, et al. Risk of invasive cervical cancer among women with, or at risk for, HIV infection. Int J Cancer 1999; 82:334-7.
70. Clark MA, Hartley A, Geh JI. Cancer of the anal canal. Lancet Oncol 2004; 5:149-57.
71. Northover JM. Epidermoid cancer of the anus-the surgeon retreats. J R Soc Med 1991; 84:389-90.
72. Arnott SJ, Cunningham D, Gallagher J, et al. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Coordinating Committee on Cancer Research. Lancet 1996; 348:1049-54.
73. Myerson RJ, Kong F, Birnbaum EH, et al. Radiation therapy for epidermoid carcinoma of the anal canal, clinical and treatment factors associated with outcome. Radiother Oncol 2001; 61:15-22.
74. Pitcher ME, Davidson TI, Fisher C, Thomas JM. Post irradiation sarcoma of soft tissue and bone. Eur J Surg Oncol 1994; 20:53-6.
75. Jephcott CR, Paltiel C, Hay J. Quality of life after non-surgical treatment of anal carcinoma: a case control study of long-term survivors. Clin Oncol (R Coll Radiol) 2004; 16:530-5.
76. Flam M, John M, Pajak TF, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 1996; 14:2527-39.
77. Gerard JP, Ayzac L, Hun D, et al. Treatment of anal canal carcinoma with high dose radiation therapy and concomitant fluorouracil-cisplatinum: long-term results in 95 patients. Radiother Oncol 1998; 46:249-56.
78. Doci R, Zucali R, Bombelli L, Montalto F, Lamonica G. Combined chemoradiation therapy for anal cancer: a report of 56 cases. Ann Surg 1992; 215:150-6.
79. John M, Flam M, Palma N. Ten-year results of chemoradiation for anal cancer: focus on late morbidity. Int J Radiat Oncol Biol Phys 1996; 34:65-9.
80. Mayeaux EJ Jr, Harper MB, Abreo F, Pope JB, Phillips GS. A comparison of the reliability of repeat cervical smears and colposcopy in patients with abnormal cervical cytology. J Fam Pract 1995; 40:57-62.
81. DiBonito L, Falconieri G, Tomasic G, Colautti I, Bonifacio D, Dudine S. Cervical cytopathology: an evaluation of its accuracy based on cytohistologic comparison. Cancer 1993; 72:3002-6.
82. Colquhoun P, Nogueras JJ, Dipasquale B, Petras R, Wexner SD, Woodhouse S. Interobserver and intraobserver bias exists in the interpretation of anal dysplasia. Dis Colon Rectum 2003; 46:1332-6; discussion 1336-8.
83. Lytwyn A, Salit IE, Raboud J, et al. Interobserver agreement in the interpretation of anal intraepithelial neoplasia. Cancer 2005; 103:1447-56.
84. Cocchi V, Carretti D, Fanti S, et al. Intralaboratory quality assurance in cervical/vaginal cytology: evaluation of intercytologist diagnostic reproducibility. Diagn Cytopathol 1997; 16:87-92.
85. Stoler MH, Schiffman M. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA 2001; 285:1500-5.
86. Woodhouse SL, Stastny JF, Styer PE, Kennedy M, Praestgaard AH, Davey DD. Interobserver variability in subclassification of squamous intraepithelial lesions: results of the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology. Arch Pathol Lab Med 1999; 123:1079-84.
87. Miller M, van Niekerk D, Granger M, et al. Self collection for anal cancer screening in gay men. Int Conf AIDS. 2004.
88. Cranston RD, Darragh TM, Holly EA, et al. Self-collected versus clinician-collected anal cytology specimens to diagnose anal intraepithelial neoplasia in HIV-positive men. J Acquir Immune Defic Syndr 2004; 36:915-20.
89. Bigrigg A, Haffenden DK, Sheehan AL, Codling BW, Read MD. Efficacy and safety of large-loop excision of the transformation zone. Lancet 1994; 343:32-4.
90. Tate DR, Anderson RJ. Recrudescence of cervical dysplasia among women who are infected with the human immunodeficiency virus: a case-control analysis. Am J Obstet Gynecol 2002; 186:880-2.
91. Nadal SR, Manzione CR, Galvao VM, Salim VR, Speranzini MB. Healing after anal fistulotomy: comparative study between HIV+ and HIV- patients. Dis Colon Rectum 1998; 41:177-9.
92. Abbasakoor F, Boulos PB. Anal intraepithelial neoplasia. Br J Surg 2005; 92:277-90.
93. Fleming P, Byers R, Sweeney P, Daniels D, Karon J, Janssen R. HIV prevalence in the United States 2000. Conference on Retroviruses and Opportunistic Infections. 2002.
94. Inadomi JM. Update on the cost-effectiveness of screening for colorectal neoplasia. Curr Opin Gastroenterol 2003; 19:44-50.
95. Freedberg KA, Scharfstein JA, Seage GR 3rd, et al. The cost-effectiveness of preventing AIDS-related opportunistic infections. JAMA 1998; 279:130-6.
96. Cress RD, Holly EA. Incidence of anal cancer in California: increased incidence among men in San Francisco, 1973-1999. Prev Med 2003; 36:555-60.
97. Christopherson WM, Mendez WM, Ahuja EM, Lundin FE Jr, Parker JE. Cervix cancer control in Louisville, Kentucky. Cancer 1970; 26:29-38.
98. Panther LA, Schlecht HP, Dezube BJ. Spectrum of human papillomavirus-related dysplasia and carcinoma of the anus in HIV-infected patients. AIDS Read 2005; 15:79-82, 85-6, 88, 91.
99. Orlando G, Fasolo MM, Beretta R, Merli S, Cargnel A. Combined surgery and cidofovir is an effective treatment for genital warts in HIV-infected patients. AIDS 2002; 16:447-50.
100. Fleshner PR, Freilich MI. Adjuvant interferon for anal condyloma: a prospective, randomized trial. Dis Colon Rectum 1994; 37:1255-9.